About the Book
A comprehensive look at current drug discovery and development methods—and the roadmap for the future Providing both understanding and guidance in characterizing potential drugs and their production and synthesis, Development of Therapeutic Agents Handbook gives professionals a basic tool to facilitate research and development within this challenging process. This comprehensive text brings together, in one resource, a compendium of concepts, approaches, methodologies, and limitations that need to be considered in the formulation of therapeutic agents across a range of therapeutic fields. Both a reference and a call to action for the pharmaceutical industry, Development of Therapeutic Agents Handbook examines recent innovations taking shape in the various medical disciplines involved in drug discovery, and shows why these advances need to be embraced universally among researchers to improve their solution strategies. Additional subject matter includes:
Extensive coverage and in-depth look into novel treatments and therapeutics
Discussion of hot topics like new drugs and nutraceuticals, the discovery and development of vaccines, cancer therapeutics, and market overviews
Coverage of therapeutic drug development for specific disease areas, such as cardiology, oncology, breast cancer, and kidney diseases
As research in biology, chemistry, medicine, and technology rapidly progresses, it is becoming increasingly important for medical researchers to maintain an up-to-date knowledge base of emerging trends directing promising new therapies. Development of Therapeutic Agents Handbook serves this purpose, acting as both a one-stop reference rich in valid science, and a tool to carve out new pathways in the pursuit of bringing safer and more effective drugs to the marketplace.
Table of Contents:
PREFACE ix CONTRIBUTORS xi
PART I FUNDAMENTAL CONCEPTS 1
1. Current Needs for New Therapeutic Agents and Discovery Strategies—A Systems Pharmacology Approach 3
Sophie C. Desbiens and David H. Farb
2. Target Selection in Drug Discovery 25
Charles F. Albright
3. New Drug Applications 35
John S. McInnes and Donald O. Beers
4. From Concept to the Clinics: Development of Cancer Therapeutics 47
Balveen Kaur, Gregory B. Lesinski, and Abhik Ray Chaudhary
5. Development of Countermeasures for Bioterrorism in the United States 73
Gregory H. Levine and Jeffrey I. Handwerker
6. Development and Application of Conformation-Selective Integrin Antibodies 91
Nathan S. Astrof, Dan Peer, and Motomu Shimaoka
7. Pain Management Market Overview 113
Anita Holdcroft
8. Antiviral Market Overview 127
Anita Arora, Natalia Mendoza, and Stephen K. Tyring
PART II METHODS AND TECHNIQUES IN DRUG DISCOVERY AND DEVELOPMENT 145
9. High-Throughput Screening for Small-Molecule Drug Discovery 147
C. Parker and J.-H. Zhang
10. Mass Spectrometry 181
Robert D. English and Anthony M. Haag
11. Molecular Screening for Therapeutic Agents 207
R. Damoiseaux
12. Accelerator Mass Spectrometry and Positron Emission Tomography in Human Microdosing 241
Zhengdong Cheng
13. Development of Antimicrobial Peptides as Therapeutic Agents 285
Robert S. Hodges, Ziqing Jiang, James Whitehurst, and Colin T. Mant
14. Antibodies for Human Diseases 359
Guo-Liang Yu and Jian Ni
15. Combinatorial Compounds and Drug Discovery 399
James C. Bigelow
16. Locoregional Chemoradiotherapy of Cancer Using Hydrogel 413
David J. Yang, Ali Azhdarinia, Hiroaki Kurihara, and E. Edmund Kim
17. RNAi-Mediated Therapeutics 425
Nuria Morral and Scott R. Witting
18. Crystallography 445
Carl H. Schwalbe
19. PEGylation 463
Sanju Dhawan, Deepak N. Kapoor, Rishi Kapil, Mano Kumarj, and Ankur Bansal
20. Gold Standard Animal Models 517
Carol Casteneda and Michael S. LaPointe
21. Discovery of Vaccine Adjuvants 533
Fiona A. Sharp and Ed C. Lavelle
22. Oral Delivery of Macromolecules for the Development of Therapeutic Agents 547
Hye J. Lee and Chanmi Choi
23. Aerosol Drug Delivery to the Lungs 565
Andrew R. Martin and Warren H. Finlay
24. Resistance to Antiplatelet Theraphy 589
Paul A. Gurbel, Udaya S. Tantry, and Mark J. Antonino
25. Antibiotic Development 611
Robert L. Bettiker and Jason C. Gallagher
PART III THERAPEUTIC TOPICS 629
26. Antimicrobial Resistance in Biofi lms: A Sticky Situation 631
Shu Yeong Queck and Michael Otto
27. Drotrecogin Alfa Activated (Recombinant Human Activated Protein C, Xigris) 645
Byungse Suh and Rafi k Samuel
28. Anti-Inflammatory Therapeutics 655
Marion M. Chan and Dunne Fong
29. Anti-Inflammatory/Analgesics: An In-depth Look at p38 MAP Kinases 673
Kelly L. Brown
30. Cardiovascular Disease: In-Depth Look 707
Nicholas B. Norgard and Mazen Abu-Fadel
31. Ezetimibe and Cholesterol Absorption 723
Stefan Oswald and Werner Siegmund
32. Cardiology—In-Depth Look: Kinases as Therapeutic Targets in the Heart 743
Karin Mauer and J. Emilio Exaire
33. Statins in the Reduction of Cardiovascular Events 773
Rajesh Sachdeva, Bradley Hughes, and Jawahar L. Mehta
34. Cardiology—In-Depth Look: Advances in Antiplatelet Theraphy 785
Karin Mauer and Jorge F. Saucedo
35. Gastrointestinal Disorders: A Focus on Acid-Suppressive Agents 813
Brian Hemstreet
36. Pharmacology of Vasopressin and the Renin—Angiotension—Aldosterone System 825
Elizabeth J. Brant and Julian L. Seifter
37. New Drugs and Nutaceutical in the Treatment of Osteoarthristis 847
Y. Henrotin and J. Y. Reginster
38. Development of Anticytokine Agents for Rheumatoid Arthritis 881
Jonathan Sherlock, Christopher D. Buckley, and Karim Raza
39. Overview of CNS Neuropharmaceuticals 897
Tauser Roxana-Georgiana and Antohe Dan-Stefan
40. Thinking Outside the Box in Alzheimer Disease Treatment 929
Rudy J. Castellani, Michael W. Marlatt, Akihiko Nunomura, Paula I. Moreira, Hyoung-Gon Lee, Gemma Casadesus, Xiogwei Zhu, George Perry, and Mark A, Smith
41. Neurotrophic Factors as Novel Therapeutic Targets 943
Stephen D. Skaper
42. Oncology 963
Arkadiusz Z. Dudek and Steven F. Powell
43. Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia 999
Muhammad Mansoor Alam and Moshe Talpaz
44. Aromatase Inhibitors for Breast Cancer 1011
Akm Hossain and Jame Abraham
45. Evolution of Selective Estrogen and Androgen Receptor Modulators: Status of Current Therapy and New Drug Development 1019
Gregory T. Wurz and Michael W. DeGregorio
46. In-Depth Look: anti-TNF-α Therapies 1045
Satadal Chatterjee and Shobhan Gaddameedhi
47. Development of Therapeutic Agents: The Maternal—Fetal Perspective 1093
C. Gedeon, F. Garcia Bournissen and G. Koren
48. History of Antipsychotic Drug Development 1111
Shankar S. Gollapudi and Rajan Radhakrishnan
49. Radiopharmaceuticals and Medical Imaging: Development of Radioimmumoconjugates for Radioimmunoimaging and Radioimmunotherapy of Malignant Diseases 1137
Gang Niu and Xiaoyuan Chen
50. Therapeutic Drug Development for Kidney Diseases 1159
Mitchell H. Rosner, Joshua King, and Peter Monteleone
51. Targeting Chemokines and Angiogenesis in Arthritis 1185
Zoltan Szekaneez and Alisa E Koch
52. Development of Therapeutic Agents: Methods and Approaches in the Development of Vaccines against Protozoan Parasites 1207
Catherine Ivory and Kris Chadee
53. Toxicology 1221
John H. Duffus
54. The Development of Phosphodiesterase 4 Inhibitors for Allergic and Nonallergic Infl ammatory Diseases of the Airways 1233
Mark A. Giembycz
INDEX 1251
About the Author :
SHAYNE COX GAD, PhD, DABT, ATS, is the Principal of Gad Consulting Services. He has more than thirty years of experience as a toxicologist, statistical consultant, manager, and consultant on research and development in the chemical, consumer product, contract testing, biotechnology, medical device, and pharmaceutical industries. He is the author of forty-two books and numerous papers, presentations, and other publications.
Review :
“The text is well-written and includes extensive references.” (Book News, 1 April 2012)
